FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956528744> ?p ?o ?g. }

• W2956528744 endingPage "646" @default.
• W2956528744 startingPage "638" @default.
• W2956528744 abstract "Background US has served as a standard surveillance tool for hepatocellular carcinoma (HCC); however, the detection rate and false referral rate with this modality are suboptimal. Purpose To evaluate the added value of perfluorobutane-enhanced US when combined with conventional B-mode US as an HCC surveillance tool in participants with liver cirrhosis. Materials and Methods This prospective multi-institution diagnostic trial (https://ClinicalTrials.gov, NCT02188901) used an intraindividual comparison design in a single arm of study participants and was conducted at five referral hospitals. Eligible participants who had liver cirrhosis related to viral hepatitis and were undergoing US for HCC surveillance were enrolled from October 2014 to August 2016. Immediately after completion of B-mode US but before performance of perfluorobutane-enhanced US, operating radiologists entered the results of B-mode US. After completion of subsequent perfluorobutane-enhanced US (Kupffer phase with or without vascular-phase US), the radiologists recorded the results. The presence of HCC was confirmed either with pathologic analysis or radiologically by using dynamic contrast material–enhanced CT or gadoxetic acid–enhanced MRI. The primary end points were the detection rate of early-stage HCC (Barcelona Clinic Liver Cancer staging system stage 0 or A) and false referral rate. The primary end points were compared in a per-participant manner by using the McNemar test. Results A total of 524 participants (mean age, 54 years ± 9 [standard deviation]) were included. Of these, 493 (94.1%) had liver cirrhosis related to the hepatitis B virus. Ten HCCs were confirmed in eight participants. The detection rate of early-stage HCC was not significantly improved by adding perfluorobutane-enhanced US to conventional B-mode US (difference, 0.4% [95% confidence interval: −0.3%, 1.1%]; P = .16). The false referral rate was significantly reduced (difference, −3.2% [95% confidence interval: −5.0%, −1.4%]; P < .001). Conclusion The addition of perfluorobutane-enhanced US to conventional B-mode US reduced the false referral rate without a significant improvement in the detection rate of early-stage hepatocellular carcinoma for surveillance in a population in which the hepatitis B virus predominated. © RSNA, 2019 Online supplemental material is available for this article." @default.
• W2956528744 created "2019-07-23" @default.
• W2956528744 creator A5000290016 @default.
• W2956528744 creator A5003581837 @default.
• W2956528744 creator A5009904795 @default.
• W2956528744 creator A5021257318 @default.
• W2956528744 creator A5023704206 @default.
• W2956528744 creator A5033375010 @default.
• W2956528744 creator A5040572805 @default.
• W2956528744 creator A5042010713 @default.
• W2956528744 creator A5042526369 @default.
• W2956528744 creator A5045238286 @default.
• W2956528744 creator A5080467464 @default.
• W2956528744 date "2019-09-01" @default.
• W2956528744 modified "2023-10-06" @default.
• W2956528744 title "Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN)" @default.
• W2956528744 cites W1548649101 @default.
• W2956528744 cites W1666636582 @default.
• W2956528744 cites W1902475470 @default.
• W2956528744 cites W1963666575 @default.
• W2956528744 cites W1986873494 @default.
• W2956528744 cites W2002167458 @default.
• W2956528744 cites W2014857216 @default.
• W2956528744 cites W2024627278 @default.
• W2956528744 cites W2033895938 @default.
• W2956528744 cites W2064605076 @default.
• W2956528744 cites W2073830661 @default.
• W2956528744 cites W2075462932 @default.
• W2956528744 cites W2084747961 @default.
• W2956528744 cites W2094636688 @default.
• W2956528744 cites W2106112359 @default.
• W2956528744 cites W2134063700 @default.
• W2956528744 cites W2138378598 @default.
• W2956528744 cites W2142601473 @default.
• W2956528744 cites W2148344195 @default.
• W2956528744 cites W2150027485 @default.
• W2956528744 cites W2153671281 @default.
• W2956528744 cites W2171104739 @default.
• W2956528744 cites W2221296005 @default.
• W2956528744 cites W2277004004 @default.
• W2956528744 cites W2468199489 @default.
• W2956528744 cites W2496240332 @default.
• W2956528744 cites W2514974872 @default.
• W2956528744 cites W2521816081 @default.
• W2956528744 cites W2544387958 @default.
• W2956528744 cites W2606278941 @default.
• W2956528744 cites W2779903773 @default.
• W2956528744 cites W2788181004 @default.
• W2956528744 cites W2796067155 @default.
• W2956528744 cites W3021655826 @default.
• W2956528744 cites W4235293299 @default.
• W2956528744 doi "https://doi.org/10.1148/radiol.2019190183" @default.
• W2956528744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31287387" @default.
• W2956528744 hasPublicationYear "2019" @default.
• W2956528744 type Work @default.
• W2956528744 sameAs 2956528744 @default.
• W2956528744 citedByCount "27" @default.
• W2956528744 countsByYear W29565287442019 @default.
• W2956528744 countsByYear W29565287442020 @default.
• W2956528744 countsByYear W29565287442021 @default.
• W2956528744 countsByYear W29565287442022 @default.
• W2956528744 countsByYear W29565287442023 @default.
• W2956528744 crossrefType "journal-article" @default.
• W2956528744 hasAuthorship W2956528744A5000290016 @default.
• W2956528744 hasAuthorship W2956528744A5003581837 @default.
• W2956528744 hasAuthorship W2956528744A5009904795 @default.
• W2956528744 hasAuthorship W2956528744A5021257318 @default.
• W2956528744 hasAuthorship W2956528744A5023704206 @default.
• W2956528744 hasAuthorship W2956528744A5033375010 @default.
• W2956528744 hasAuthorship W2956528744A5040572805 @default.
• W2956528744 hasAuthorship W2956528744A5042010713 @default.
• W2956528744 hasAuthorship W2956528744A5042526369 @default.
• W2956528744 hasAuthorship W2956528744A5045238286 @default.
• W2956528744 hasAuthorship W2956528744A5080467464 @default.
• W2956528744 hasBestOaLocation W29565287441 @default.
• W2956528744 hasConcept C105795698 @default.
• W2956528744 hasConcept C126322002 @default.
• W2956528744 hasConcept C126838900 @default.
• W2956528744 hasConcept C186282968 @default.
• W2956528744 hasConcept C188816634 @default.
• W2956528744 hasConcept C2776135927 @default.
• W2956528744 hasConcept C2777214474 @default.
• W2956528744 hasConcept C2777382497 @default.
• W2956528744 hasConcept C2778019345 @default.
• W2956528744 hasConcept C2989005 @default.
• W2956528744 hasConcept C33923547 @default.
• W2956528744 hasConcept C40993552 @default.
• W2956528744 hasConcept C512399662 @default.
• W2956528744 hasConcept C71924100 @default.
• W2956528744 hasConceptScore W2956528744C105795698 @default.
• W2956528744 hasConceptScore W2956528744C126322002 @default.
• W2956528744 hasConceptScore W2956528744C126838900 @default.
• W2956528744 hasConceptScore W2956528744C186282968 @default.
• W2956528744 hasConceptScore W2956528744C188816634 @default.
• W2956528744 hasConceptScore W2956528744C2776135927 @default.
• W2956528744 hasConceptScore W2956528744C2777214474 @default.
• W2956528744 hasConceptScore W2956528744C2777382497 @default.
• W2956528744 hasConceptScore W2956528744C2778019345 @default.

• next